Title: Aberrant gliogenesis and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids

Authors:

Dorit Trudler^{1†}, Swagata Ghatak^{1†}, James Parker², Maria Talantova¹, Titas Grabauskas¹, Sarah Moore Noveral², Mayu Teranaka², Melissa Luevanos¹, Nima Dolatabadi¹, Clare Bakker¹, Kevin Lopez², Abdullah Sultan², Agnes Chan³, Yongwook Choi³, Riki Kawaguchi⁴, Nicholas Schork^{3,5}, Pawel Stankiewicz⁶, Ivan Garcia-Bassets⁷, Piotr Kozbial⁷, Michael G. Rosenfeld⁷, Nobuki Nakanishi², Daniel H. Geschwind⁸, Shing Fai Chan^{9*}, Rajesh Ambasudhan^{1,2}, Stuart A. Lipton^{1,2,10¶}

Affiliations:

¹Neuroscience Translational Center and Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.

²Neurodegenerative Disease Center, Scintillon Institute, San Diego, California 92121, USA.

³Translational Genomics Research Institute, Phoenix, Arizona 85004, USA.

⁴Departments of Psychiatry and Neurology, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA.

⁵Departments of Psychiatry and Family Medicine and Public Health, University of California, San Diego, La Jolla, California 92037, USA.

⁶Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA

⁷Howard Hughes Medical Institute, School and Department of Medicine, University of California, San Diego School of Medicine, La Jolla, California 92093, USA

⁸Department of Neurology, Center for Autism Research and Treatment; Program in Neurobehavioral Genetics; Department of Human Genetics; Department of Psychiatry, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA.

⁹Center for Neuroscience, Aging, and Stem Cell Research, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, USA.

¹⁰Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, California 92093, USA.

[†]These authors contributed equally

^{*}Present address: Department of Medicine, Indiana University-Purdue University, Indianapolis, IN, USA

[¶]Correspondence regarding the manuscript should be addressed to S.A.L. (slipton@scripps.edu).

Short Title: hiPSC models of MEF2C haploinsufficiency

One sentence summary: Autism-like MEF2C^{+/-} patient hiPSC models show miRNA-mediated overproduction of astrocytes and hyperactivity of neurons.

Abstract:

MEF2C has been shown to be a critical transcription factor for neurodevelopment, whose loss-of-function mutation in humans results in MEF2C haploinsufficiency syndrome (MHS), a severe form of autism spectrum disorder (ASD)/intellectual disability (ID). Here, we use patient hiPSC-derived cerebrocortical neurons and cerebral organoids to characterize MHS deficits. Unexpectedly, we found an aberrant micro-RNA-mediated gliogenesis pathway that contributes to decreased neurogenesis. We also demonstrate network-level hyperexcitability in neurons, as evidenced by excessive synaptic and extrasynaptic activity contributing to excitatory/inhibitory (E/I) imbalance. Notably, the extrasynaptic NMDA receptor antagonist, NitroSynapsin, corrects this aberrant electrical activity associated with abnormal phenotypes. During neurodevelopment, MEF2C regulates many ASD-associated gene networks suggesting that our approach may lead to personalized therapy for multiple forms of ASD.

Main Text:

Autism spectrum disorder (ASD) is a group of neurodevelopmental disabilities characterized by impaired social interaction and communication, accompanied by stereotyped behaviors and restricted interests (1).

It is estimated that 1 in 54 American children develop ASD (1-3). Despite extensive research that identified various genetic mutations (e.g., *MECP2*, *SHANK1-3*, *NRXN1-3*, etc.) and environmental factors, which are contributory to its etiology (4, 5), the molecular mechanisms underlying ASD remain largely unknown, hindering the development of robust diagnostics and effective therapies in this field.

Myocyte enhancer factor 2 (MEF2) comprises a family of transcription factors, which belong to the MADS (MCM1-agamous-deficiens-serum response factor) gene family (6-10), with four isoforms that play a role in development, cell differentiation, and organogenesis (11). After discovering the MEF2C isoform and showing it is the first family member expressed during brain development (6, 7), we and others demonstrated its role in neurogenesis, synaptogenesis, and neuronal survival (12-15).

Subsequently, murine brain-specific knockout of *MEF2C* at early developmental stages was shown to display electrophysiological, histological, and behavioral deficits reminiscent of Rett syndrome (RTT), a severe form of ASD and intellectual disability (ID) (12, 16, 17). In fact, the gene responsible for RTT, *MECP2*, is known to influence the expression level of MEF2C and vice-versa (18, 19).

Human genetic studies subsequently established an association between *MEF2C* and human ASD/ID. Morrow et al. identified various MEF2 target genes in their screen for autism genes in human pedigrees with shared ancestry (20). Moreover MEF2C activity transcriptionally regulates many other genes that have been linked to ASD (21, 22). Recently, human studies from multiple laboratories pointed to defects in *MEF2C* itself in ASD, and *MEF2C* haploinsufficiency was identified as the cause for a severe form of ASD/ID in patients with little or no speech output, stereotypic movements, and learning/memory disorder, often accompanied by epilepsy (23-26). These studies estimated that as many as 1.1% of patients with ASD or ID manifest a *MEF2C* abnormality as an autosomal dominant cause. Disorders associated with *MEF2C* haploinsufficiency have been collectively termed *MEF2C*

haploinsufficiency syndrome (MHS) (26). Importantly, recent comprehensive transcriptome analyses of autistic brains identified *MEF2C* as one of the frequently dysregulated genes in children with ASD even without *MEF2* mutations *per se* (21, 22, 27, 28). For example, a histone-wide association study suggested that the *MEF2C* locus is dysregulated in ASD patients with other etiologies in addition to MHS (29). Collectively, these data argue that finding a successful treatment for the *MEF2C* haploinsufficiency form of ASD may in fact benefit other forms of ASD as well.

Despite prior animal studies of *MEF2C* heterozygosity to mimic MHS (16, 30, 31), mechanisms whereby *MEF2C* affects neuronal development in the human context of ASD are still poorly understood. Accordingly, here we used MHS patient-derived human induced pluripotent stem cells (hiPSCs) and CRISPR/Cas9 technology for isogenic controls to generate cerebrocortical neurons in 2-dimensional (2D) cultures and 3D cerebral organoids. This approach allowed us to study human neuronal development and function in the presence of control (Ctrl) or patient-relevant mutations in *MEF2C*, and thus to tease out molecular and electrophysiological mechanisms underlying MHS pathophysiology.

Altered differentiation of MHS hiPSC-derived neurons

To study the molecular mechanisms of MHS in human context, we generated hiPSC lines from dermal fibroblasts of 3 patients (MHS-P1, MHS-P3, MHS-P4) bearing a microdeletion or point mutation in *MEF2C*. As controls, we used gender-matched samples of similar ages consisting of well-characterized hiPSC lines (Ctrl2 and Ctrl3) (32). Additionally, using CRISPR/Cas9, we generated an hiPSC line with a microdeletion in *MEF2C* (designated MHS-P2) that could be compared to its cognate isogenic control (Ctrl1; see **table S1**). In total, we analyzed 4 hiPSC lines with mutations in *MEF2C* and 3 control lines. All hiPSC lines were characterized and found to be karyotypically normal, positive for pluripotency markers, and capable of differentiating into all germ layers (**fig. S1**). We differentiated the hiPSCs into cerebrocortical neurons using a dual-SMAD inhibition protocol (33, 34). Both MHS patient and Ctrl hiPSCs efficiently generated neural progenitor cells (NPCs), as detected by immunofluorescent labeling

with Nestin and SOX2 (**fig. S2A**). The cells were subsequently differentiated into cerebrocortical neurons (hiPSC-neurons) expressing pan-neuronal markers, including β 3-tubulin and microtubule associated protein 2 (MAP2). Our differentiation protocol yielded both excitatory and inhibitory neurons, as well as astrocytes (33).

To begin to assess the differentiation capacity of the various hiPSC lines, we analyzed neuronal- and astrocyte-selective markers (MAP2 and glial acidic fibrillary protein (GFAP) or S100 β , respectively) after 1 month of differentiation from hNPCs. Compared to Ctrl1, we discovered that hNPCs bearing an MHS-related mutations generated more astrocytes, as detected by GFAP and S100 β , and fewer MAP2-positive neurons (**Fig. 1, A to C, and fig. S2, B and C**). We also found lower levels of MAP2 protein, as detected by immunoblot (**Fig. 1, D to F**). MAP2 levels were similarly lower in 3-month-old neuronal cultures (**fig. S2, D and E**), indicating that this effect does not appear only at early stages of development, and persists.

Additionally, as cells were transitioning from hNPCs to neurons during the first week of terminal differentiation, we performed MEF2-reporter gene assays to begin to assess whether MEF2C participates in the early stages of neuronal differentiation and maturation. We found that the human neurons generated from hiPSCs bearing MHS-relevant mutations (MHS hiPSC-neurons) had lower MEF2 luciferase activity, consistent with haploinsufficiency (**Fig. 1G**). Electrophysiologically, we found that the decrease in MEF2 reporter gene activity correlated with hyperexcitability at both the single neuron and network level that developed within 5 weeks of neuronal differentiation. For example, MHS hiPSC-neurons showed an ~2-fold increase in frequency of spontaneous action potentials when compared to Ctrl hiPSC-neurons (**Fig. 1, H to J**). We observed this effect for all patient-relevant mutations except MHS-P1, which manifested an increase in spontaneous action potentials at the single neuron level compared to Ctrl2 and Ctrl3 but not Ctrl1 (**Fig. 1, H and I**). This finding may reflect the lack of seizures in this patient compared to the others (**table S1**). Note that evoked action potential frequency and other action potential

parameters, including firing threshold, height and half-width, did not show any significant differences between MHS and Ctrl hiPSC-neurons (**fig. S4 and table S2**).

Transcriptomic effects on MHS hNPCs drive the astrocytic phenotype and limit neurogenesis

To understand mechanistically how MEF2C affects differentiation into neurons, we performed chromatin immunoprecipitation-sequencing (ChIP-seq) analysis on control hNPCs for MEF2C binding sites, using methods we have detailed previously (35, 36) (**Fig. 2, A and B and fig. S3**). We found 198 such targets (**table S3**), many of which were enriched for gene ontology (GO) terms related to neurological diseases, cell growth, and proliferation (**Fig. 2A**). Interestingly, five of these MEF2C targets encoded microRNAs (miRNAs) thought to be involved in neurogenesis as opposed to gliogenesis (37, 38), so we focused on these (**Fig. 2B**). We first validated the miRNA results using hNPCs that express a constitutively active form of MEF2C (39-41) and found that three miRNAs, miR663a, miR663b and miR4273, all of which have binding sites on astrocytic-expressed mRNAs (42), manifested higher expression when MEF2C was active (**Fig. 2C**). We then found that patient MHS cells had lower expression of all three of these miRNAs (**Fig. 2D**). When we inhibited the expression of miR663a and miR4273 in Ctrl hNPCs to mimic the effect of haploinsufficiency, we found that the cells recapitulated MHS hiPSC phenotypes, i.e., differentiating mainly into astrocytes and far fewer neurons, as detected by S100 β and β 3-tubulin (TUJ1), respectively (**Fig. 2, E and F**). These findings are consistent with the notion that suppression of these miRNAs in MHS patient cells contributes to progenitor differentiation into fewer neurons and more astrocytes (**Fig. 2G**).

Next, using methods we have described (43), we performed RNA-sequencing (RNA-seq) to detect changes in gene expression between MHS and Ctrl cells after 5 weeks of neuronal differentiation. Previously, we had shown that MEF2C predominantly targets neuronally-restricted gene promoters starting at the hNPC stage (40), so we focused our analysis on neuron-associated genes. We identified neuronal genes by their gene ontology (GO) terms (**Fig. 2H**). Among these, several were very highly

expressed in neurons compared to astrocytes or other cells types (**Fig. 2, I and J**). Neurexin3 (*NRXN3*) was of particular interest because of its known involvement in neuronal development and function (44). Interestingly, neurexins have been associated with ASD, and high or low expression can be detrimental, pointing to a bell-curve effect as found for MEF2C (45), with an optimal dose of neurexin critical for normal brain development (46). Furthermore, region- and context-specific effects of alterations in *NRXN3* have been demonstrated (44). Along these lines, we found that *NRXN3* was increased in MHS patient hiPSC-neurons compared to Ctrl (**Fig. 2K and L**). Our ChIP-seq and RNA-seq results support the notion that MHS hiPSC-derived cells manifest dysfunctional neurogenesis, increased gliogenesis, and aberrant neuronal differentiation, which we therefore investigated further.

MHS hiPSC-neurons show enhanced glutamate-mediated currents and decreased GABA-mediated currents

Since both MEF2C and *NRXN3* are particularly important for the development of synapses (12, 17, 30, 31, 44, 47), we next sought to understand if MHS hiPSC-neurons exhibit differential excitatory and inhibitory activity. We performed patch-clamp electrophysiological recordings on neurons plated on primary mouse astrocytes to enhance synaptic interactions (48). Initially, we studied ligand-gated channels. During whole-cell recordings we found the current density elicited by exogenous glutamate application to be 2-4-fold greater in MHS hiPSC-neurons than Ctrl (**Fig. 3, A and B**). In contrast, we found significantly decreased GABA-evoked current density in MHS hiPSC-neurons (**Fig. 3, A and C**). Taken together, this resulted in a robust increase in the glutamate to GABA current ratio (**Fig. 3D**).

Next, we monitored evoked excitatory synaptic activity. Compared to control hiPSC-neurons, we found a statistically significant increase for MHS-P2-4 (with a trend for MHS-P1) in the NMDA receptor-mediated component of excitatory postsynaptic currents (NMDAR-EPSCs), monitored at +60 mV to ensure removal of Mg^{2+} block by depolarization. There was also an increase in the AMPA receptor-mediated component (AMPA-EPSCs), measured at -70 mV to ensure separation from the NMDAR-

mediated component by blocking NMDAR-operated channels via hyperpolarization-induced Mg^{2+} block (**Fig. 3, E to I**). Too few evoked inhibitory synaptic currents were observed under our conditions to quantify, possibly because of prior findings from the Fishell group showing that MEF2C also plays a role in generating parvalbumin (PV)-positive GABAergic interneurons and as our group has reported in MHS-model mice (31, 49). Other electrophysiological parameters, including resting membrane potential, cell capacitance, and sodium- and potassium-current density, were similar among MHS and Ctrl hiPSC-neurons (**table S2**).

MHS hiPSC-neurons exhibit disrupted spontaneous synaptic transmission

To further examine differences between excitatory and inhibitory signaling, we next focused on spontaneous synaptic activity. We observed a statistically significant increase in the frequency of spontaneous (s)EPSCs in all MHS hiPSC-neurons except MHS-P1, which manifested a trend in this direction (**fig. S5, A and C**). Additionally, sEPSCs recorded from MHS-P3 and -4 exhibited increased amplitude compared to Ctrl hiPSC-neurons (**fig. S5, A and B**). Concerning spontaneous miniature EPSCs (mEPSCs), we found an increase in frequency with no change in amplitude for most MHS hiPSC-neurons (**Fig. 4, A to C**). MHS-P3, however, displayed a small increase in mEPSC amplitude. In contrast to increased excitatory synaptic transmission, we observed a significant decrease in the frequency of spontaneous and miniature inhibitory postsynaptic currents (sIPSCs and mIPSCs) in MHS hiPSC-neurons compared to Ctrl, without a significant change in amplitude (**Fig. 4, D to F; fig. S5, D to F**). Notably, we had previously reported similar findings in a *MEF2C* heterozygous mouse model of MHS that displays increased excitatory synaptic transmission and decreased inhibitory synaptic transmission (31).

The increase in mEPSC and decrease in mIPSC frequencies may reflect alterations in presynaptic mechanisms, such as quantal release, or a change in excitatory and inhibitory synapse numbers, or both types of effects. To begin to distinguish between these possibilities, we performed a series of

immunocytochemical experiments to monitor synaptic properties. Initially, we measured the total number of excitatory synapses by counting co-localized punctae of presynaptic synapsin I and postsynaptic PSD-95, and found that MHS hiPSC-neurons displayed a moderate, statistically significant decrease in the total number of synapses compared to Ctrl (**fig. S6**). Next, we monitored presynaptic vesicle proteins and observed an increase in vesicular glutamate transporter (VGLUT1) staining but a decrease in vesicular GABA transporter (VGAT), resulting in an increase in the ratio of VGLUT1 to VGAT in MHS hiPSC-neurons compared to Ctrl (**Fig. 4, G to K**). These changes are similar to those we had observed in *MEF2C* heterozygous mice (31) and consistent with a presynaptic effect on neurotransmission. The findings on excitatory presynaptic terminals may reflect in part the known action of NRXN3 on VGLUT1 expression and clustering (44, 46, 47). Collectively, our results are consistent with the notion that despite a decrease in the total number of excitatory synapses, MHS hiPSC-neurons may exhibit enhanced presynaptic release, resulting in an overall increase in excitatory neurotransmission. Moreover, in addition to its role in neurogenesis and synaptogenesis during development (12), *MEF2C* is also known to play a critical role in excitatory synaptic pruning once synapses have been formed (15, 50-52). Hence, the relative deficit in *MEF2C* transcriptional activity in MHS hiPSC-neurons compared to Ctrl could also contribute to the increase in mEPSC frequency as a result of decreased excitatory synaptic pruning of MHS hiPSC-neurons as they mature. In contrast to excitatory neurotransmission, we found that inhibitory transmission is relatively depressed by both electrophysiological and histological parameters in MHS hiPSC-neurons. Taken together, the increase in excitation and decrease in inhibition that we observed in MHS hiPSC-neurons may lead to hyperexcitability in the neural network, thus contributing to ASD-like pathophysiology in MHS patients. Therefore, in the next series of experiments we investigated the properties of neural network activity in MHS vs. Ctrl using hiPSC-derived 2D cultures and 3D cerebral organoids.

MHS hiPSC-neurons exhibit enhanced neural network activity, reflected in spontaneous calcium transients and multi-electrode array recordings, that can be normalized by the extrasynaptic NMDAR antagonist NitroSynapsin

Initially, to investigate neural network activity in a population of neurons simultaneously, we monitored Ca^{2+} transients in 2D cultures. MHS hiPSC-neuronal cell bodies displayed an increase in spontaneous Ca^{2+} transient frequency compared to Ctrl, as monitored with the single-wavelength fluorescent Ca^{2+} indicator Fluo-4 (**Fig. 5, A and B and movies S1 and S2**). Treatment with the NMDAR antagonist NitroSynapsin normalized the aberrantly high intracellular Ca^{2+} levels and Ca^{2+} transient frequency in MHS hiPSC-neurons toward Ctrl values (**Fig. 5, C to E and movie S3**). The concentration of drug used in these experiments was determined from our previously published dose-response curves that found 5-10 μM NitroSynapsin to be maximally efficacious and also attainable in vivo (31, 32, 53). Notably, we had previously reported that NitroSynapsin ameliorates E/I imbalance in MHS-model mice, normalizing their aberrant synaptic activity, histological deficits, and ASD-like behavioral phenotypes (31).

Mechanistically, we and others have shown that compounds in the aminoadamantane class, such as memantine and the more efficacious NitroSynapsin, preferentially block extrasynaptic (e)NMDARs over synaptic receptors at the concentrations utilized here (32, 53-55). Therefore, we next studied eNMDAR-mediated currents in Ctrl and MHS hiPSC-neurons. eNMDAR-associated responses were isolated pharmacologically using a previously published protocol (32, 56). Under these conditions, MHS hiPSC-neurons manifested an increase in basal eNMDAR-mediated intracellular calcium responses compared to Ctrl (**fig. S7, A to C**), apparently due to an increase in basal extracellular glutamate levels in the MHS cultures (32, 56). Critically, we found that NitroSynapsin could significantly decrease the eNMDAR-mediated calcium responses in MHS cultures (**fig. S7, A and B**). Moreover, treatment with TTX abrogated the increase in basal eNMDAR-mediated extrasynaptic currents in MHS cultures and thus the effect of NitroSynapsin, consistent with the notion that excessive excitatory synaptic activity (as shown in **Figs. 3 and 4**) caused glutamate spillover and consequently an increase in basal eNMDAR-

mediated current (**fig. S7C**) (31, 32, 57). Additionally, (2R)-amino-5-phosphonovalerate (APV), a competitive NMDAR antagonist, decreased the extrasynaptic currents in MHS cultures, corroborating the notion that the currents inhibited by NitroSynapsin were indeed due to aberrantly active eNMDARs (**fig. S7D**).

Next, we confirmed the presence of aberrantly increased basal eNMDAR-mediated currents in MHS cultures by patch-clamp electrophysiological recordings. We found that MHS but not Ctrl hiPSC-neurons manifested basal eNMDAR-mediated current after pharmacological isolation of this current (58), and NitroSynapsin inhibited the current (**fig. S7E**). eNMDAR-mediated currents in spatially-compact neurons would be expected to depolarize their presynaptic terminals and thus alter excitatory synaptic activity. Along these lines, prior studies have shown that aberrant eNMDAR activity can increase mEPSC frequency, probably by increasing presynaptic release of glutamate, as seen here (59, 60). Thus, increased eNMDAR currents can lead to a type of feed-forward hyperexcitability, as observed in MHS hiPSC-neurons, and normalizing eNMDAR activity, e.g., with NitroSynapsin, could be critical in rebalancing the neural circuit.

To further explore this effect of excessive eNMDAR activity due to MEF2C haploinsufficiency on neural network activity, we employed multielectrode array (MEA) recordings in our Ctrl and MHS cultures. Similar to our measurements of Ca^{2+} transient activity, in MHS cultures compared to Ctrl we found an increase in mean firing rate, electrode burst frequency (reflecting primarily single neuron action potentials), network burst frequency (reflecting action potentials of multiple neurons), and synchronicity of firing (**Fig. 5, F to J**). Notably, treatment with NitroSynapsin, to block excessive eNMDAR-mediated currents, significantly decreased all of these parameters of aberrant hypersynchronous firing in MHS hiPSC-neuronal cultures while not affecting Ctrl cultures (**Fig. 5, F to J**).

NitroSynapsin corrects hypersynchronous excessive activity in MHS cerebral organoids

To further validate our results in a more complex system, we next used hiPSC-derived cerebral organoids (61), a model system that allows us to study neuronal circuits in 3D, and better reflects in vivo microcircuits (**fig. S8A**). We characterized our MHS and Ctrl cerebral organoids histologically at various time points to confirm the presence of neurons and astrocytes. For example, we found that by 2-months in culture, MHS cerebral organoids compared to Ctrl were smaller in size (**fig. S8, A and B**), similar to human MHS patient brains in both children and adults (22, 24). We found that MHS cerebral organoids recapitulated the 2D culture finding of a decreased proportion of neurons and neuropil compared to Ctrl, as judged by quantitative confocal immunofluorescence for β 3-tubulin corrected for cell number (**fig. S8, C to E**). We also observed a significant increase in GFAP expression by quantitative confocal immunostaining and by quantitative (q)PCR, but no difference in astrocyte-specific S100 β staining (**fig. S8, C, F to K**). Since GFAP labels both radial glial cells/neural precursors and astrocytes but S100 β only astrocytes, this finding may be attributed to the developmental stage of these organoids, at which time point neural progenitors were prominent and gliogenesis was just beginning (62-64). MHS cerebral organoids also showed an increase in Nestin-positive hNPCs, indicating an abnormal build-up of early neural progenitors compared to Ctrl (**fig. S9, A and B**). On the other hand, we found a decrease in TBR2 labeling in MHS cerebral organoids, consistent with fewer intermediate progenitor cells compared to Ctrl and suggestive of a delay in development at this stage (**fig. S9, A and C**). There was also evidence for disruption of cortical layer formation in the MHS compared to Ctrl organoids, similar to that reported for conditional knockout of *MEF2C* in mouse brain (12-15). Along these lines, CTIP2, a cerebrocortical layer V-VI marker, and TBR1, a cortical layer VI marker, were markedly decreased in expression in MHS cerebral organoids compared to Ctrl (**fig. S9, A, D and E**).

In MEA recordings, we found a dramatic increase in electrical activity in MHS cerebral organoids compared to Ctrl (**Fig. 6, A, B and D**). Similar to our 2D cultures described above, MHS organoids showed increased frequency of network bursts and firing synchrony compared to Ctrl (**Fig. 6, E and F**). Importantly, NitroSynapsin normalized the excessive mean firing rate, network burst frequency,

and firing synchrony of the MHS cerebral organoids virtually to Ctrl levels, while having minimal effect on Ctrl organoids (**Fig. 6, C to F**).

Discussion

As demonstrated in murine models, MEF2C plays a critical role during development to shape neuronal connectivity (15, 31). At early developmental stages, MEF2C is important for transcription of neuronally restricted genes and for the differentiation of hNPCs into neurons (12). In addition, MEF2C regulates formation and spread of dendrites, contributing to dendritic complexity and synapse formation, ensuring structural integrity of the neural network (12, 15, 31, 65). In contrast, at slightly later stages of development onward, MEF2C plays an important role in excitatory synapse pruning, promoting the formation and maintenance of the adult neural network (50, 66). Interestingly, heterozygosity for *MEF2C* in mice, mimicking human MHS patients, results in increased electrical excitability (31). Here, for the first time using patient-derived hiPSCs bearing MEF2C mutations, we investigated the effect of MEF2C on developing human neurons in the context of the MHS form of ASD/ID. We show that MEF2C haploinsufficiency yields cultures with more astrocytes and fewer neurons, at least in part due to aberrant miRNA expression. Furthermore, we found that while the total number of excitatory synapses was decreased on histological studies in MHS hiPSC-neurons compared to controls, there was an increase in VGLUT1 vesicular protein expression in excitatory presynaptic terminals and increased mEPSC frequency. These findings are also reflected in the increased excitability that we observed in network recordings from MHS hiPSC-neurons, in some cases resembling MHS patient seizures (**movie S2**). MHS hiPSC-neurons also displayed an increase in extrasynaptic activity, specifically, mediated by eNMDARs, consistent with overflow of neurotransmitter from hyperactive excitatory synapses (schematically summarized in **fig. S10**).

In mice, MEF2C has also been shown to regulate genes involved in inhibitory synapse formation (51), and is essential for the development of PV-expressing inhibitory neurons (49). In MHS hiPSC-

neurons, we found decreased expression of the inhibitory vesicular protein VGAT accompanied by a decrease in mIPSC frequency, revealing dysfunctional inhibitory synapse activity. Along similar lines, systemic MEF2C haploinsufficiency in mice (with lower MEF2 activity as seen in human MHS patients) resulted in decreased mIPSC frequency (31). Seemingly in contrast to these findings, conditional knockout of *MEF2C* in embryonic cortical excitatory neurons (using *Emx1*^{Cre/+} knock-in mice crossed with *MEF2C*^{fl/fl} mice) led to a moderate decrease in excitatory transmission and a large increase in inhibitory transmission (17). However, those findings were the result of excitatory neuron-specific deletion of *MEF2C*, while inhibitory neurons were spared, since cortical excitatory neurons and glia but not GABAergic neurons are produced in the *Emx1*-expressing lineage (67). Notably, a similar decrease in excitatory synaptic activity was observed with conditional brain knockout of *MEF2C* in *Nestin-Cre*⁺/*MEF2C*^{fl/Δ2} conditional null mice (where Δ2 represents exon 2-deleted allele) (12), arguing that this phenotype is due to complete loss of MEF2C activity at a very early stage of development.

As found in the present study in MHS hiPSC-derived human neurons, where approximately half of MEF2C activity is lost, the increase in excitatory synaptic and extrasynaptic activity as well as the decrease in inhibitory synaptic transmission disrupts the excitatory-inhibitory (E/I) ratio. This contributes to hypersynchronous burst activity in neural networks. Several studies have associated E/I imbalance with ASD (31, 68-70). Critically, as in *MEF2C* heterozygous mice (31, 68), we found that the eNMDAR-preferring antagonist, NitroSynapsin, abrogated the aberrant network hyperactivity in MHS hiPSC-derived neuronal cultures and cerebral organoids, suggesting that this drug merits further study for its therapeutic potential. Moreover, since MEF2C has been shown to regulate expression of many hub genes known to be associated with ASD/ID (21, 22, 43), a similar approach may prove effective in these other forms of ASD/ID.

REFERENCES AND NOTES

1. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force., *Diagnostic and statistical manual of mental disorders : DSM-5*. (American Psychiatric Association, Washington, D.C., ed. 5th, 2013), pp. xlv, 947 p.
2. C. Home, Prevalence of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010. (2014).
3. <https://www.nimh.nih.gov/health/statistics/autism-spectrum-disorder-asd.shtml>
4. I. Hertz-Picciotto *et al.*, The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. *Environ. Health Perspect.* **114**, 1119-1125 (2006).
5. Y. S. Kim, B. L. Leventhal, Genetic epidemiology and insights into interactive genetic and environmental effects in autism spectrum disorders. *Biol. Psychiatry* **77**, 66-74 (2015).
6. D. Leifer *et al.*, MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 1546-1550 (1993).
7. J. F. Martin, J. J. Schwarz, E. N. Olson, Myocyte enhancer factor (MEF) 2C: a tissue-restricted member of the MEF-2 family of transcription factors. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 5282-5286 (1993).
8. L. A. Gossett, D. J. Kelvin, E. A. Sternberg, E. N. Olson, A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes. *Mol. Cell Biol.* **9**, 5022-5033 (1989).
9. R. Pollock, R. Treisman, Human SRF-related proteins: DNA-binding properties and potential regulatory targets. *Genes Dev.* **5**, 2327-2341 (1991).
10. Y. T. Yu *et al.*, Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. *Genes Dev.* **6**, 1783-1798 (1992).
11. M. J. Potthoff, E. N. Olson, MEF2: a central regulator of diverse developmental programs. *Development* **134**, 4131-4140 (2007).
12. H. Li *et al.*, Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 9397-9402 (2008).
13. Z. Li *et al.*, Myocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cells. *J. Neurosci.* **28**, 6557-6568 (2008).
14. Z. Mao, A. Bonni, F. Xia, M. Nadal-Vicens, M. E. Greenberg, Neuronal activity-dependent cell survival mediated by transcription factor MEF2. *Science* **286**, 785-790 (1999).
15. A. C. Barbosa *et al.*, MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 9391-9396 (2008).
16. A. J. Harrington *et al.*, MEF2C hypofunction in neuronal and neuroimmune populations produces MEF2C haploinsufficiency syndrome-like behaviors in mice. *Biol. Psychiatry*, (2020).
17. A. J. Harrington *et al.*, MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders. *Elife* **5**, (2016).
18. M. Chahrour *et al.*, MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* **320**, 1224-1229 (2008).
19. M. Zweier *et al.*, Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression. *Human mutation* **31**, 722-733 (2010).
20. E. M. Morrow *et al.*, Identifying autism loci and genes by tracing recent shared ancestry. *Science* **321**, 218-223 (2008).
21. N. N. Parikshak *et al.*, Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. *Cell* **155**, 1008-1021 (2013).
22. C. Gilissen *et al.*, Genome sequencing identifies major causes of severe intellectual disability. *Nature* **511**, 344-347 (2014).

23. N. Le Meur *et al.*, MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. *J. Med. Genet.* **47**, 22-29 (2010).
24. F. Novara *et al.*, Refining the phenotype associated with MEF2C haploinsufficiency. *Clin. Genet.* **78**, 471-477 (2010).
25. B. A. Nowakowska *et al.*, Severe mental retardation, seizures, and hypotonia due to deletions of MEF2C. *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* **153B**, 1042-1051 (2010).
26. A. R. Paciorkowski *et al.*, MEF2C haploinsufficiency features consistent hyperkinesia, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways. *Neurogenetics* **14**, 99-111 (2013).
27. I. Voineagu *et al.*, Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature* **474**, 380-384 (2011).
28. G. Konopka *et al.*, Human-specific transcriptional networks in the brain. *Neuron* **75**, 601-617 (2012).
29. W. Sun *et al.*, Histone acetylome-wide association study of autism spectrum disorder. *Cell* **167**, 1385-1397 e1311 (2016).
30. A. Assali, A. J. Harrington, C. W. Cowan, Emerging roles for MEF2 in brain development and mental disorders. *Curr. Opin. Neurobiol.* **59**, 49-58 (2019).
31. S. Tu *et al.*, NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. *Nat. Commun.* **8**, 1488 (2017).
32. M. Talantova *et al.*, A β induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc. Natl. Acad. Sci. U.S.A.* **110**, E2518-E2527 (2013).
33. S. Ghatak *et al.*, Mechanisms of hyperexcitability in Alzheimer's disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. *Elife* **8**, e50333 (2019).
34. S. M. Chambers *et al.*, Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* **27**, 275-280 (2009).
35. I. Garcia-Bassets *et al.*, Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. *Cell* **128**, 505-518 (2007).
36. P. Zhu *et al.*, Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. *Cell* **124**, 615-629 (2006).
37. R. Shu *et al.*, APP intracellular domain acts as a transcriptional regulator of miR-663 suppressing neuronal differentiation. *Cell Death Dis* **6**, e1651 (2015).
38. H. Kawahara, T. Imai, H. Okano, MicroRNAs in neural stem cells and neurogenesis. *Front. Neurosci.* **6**, 30 (2012).
39. S. D. Ryan *et al.*, Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1 α transcription. *Cell* **155**, 1351-1364 (2013).
40. S. F. Chan *et al.*, Transcriptional profiling of MEF2-regulated genes in human neural progenitor cells derived from embryonic stem cells. *Genom. Data* **3**, 24-27 (2015).
41. J. A. Cho, H. Park, E. H. Lim, K. W. Lee, MicroRNA expression profiling in neurogenesis of adipose tissue-derived stem cells. *J. Genet.* **90**, 81-93 (2011).
42. A. D. Rouillard *et al.*, The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. *Database (Oxford)* **2016**, (2016).
43. N. N. Parikshak *et al.*, Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. *Nature* **540**, 423-427 (2016).
44. T. C. Sudhof, Synaptic neurexin complexes: a molecular code for the logic of neural circuits. *Cell* **171**, 745-769 (2017).
45. F. Bai *et al.*, Directed differentiation of embryonic stem cells into cardiomyocytes by bacterial injection of defined transcription factors. *Sci. Rep.* **5**, 15014 (2015).
46. A. C. Reichelt, R. J. Rodgers, S. J. Clapcote, The role of neurexins in schizophrenia and autistic spectrum disorder. *Neuropharmacology* **62**, 1519-1526 (2012).

47. S. Restrepo, N. J. Langer, K. A. Nelson, J. Aoto, Modeling a neurexin-3 α human mutation in mouse neurons identifies a novel role in the regulation of transsynaptic signaling and neurotransmitter release at excitatory synapses. *J. Neurosci.* **39**, 9065-9082 (2019).
48. E. M. Ullian, S. K. Sapperstein, K. S. Christopherson, B. A. Barres, Control of synapse number by glia. *Science* **291**, 657-661 (2001).
49. C. Mayer *et al.*, Developmental diversification of cortical inhibitory interneurons. *Nature* **555**, 457-462 (2018).
50. S. W. Flavell *et al.*, Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. *Science* **311**, 1008-1012 (2006).
51. S. W. Flavell *et al.*, Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. *Neuron* **60**, 1022-1038 (2008).
52. A. Shalizi *et al.*, A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. *Science* **311**, 1012-1017 (2006).
53. H. Takahashi *et al.*, Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. *Sci. Rep.* **5**, 14781 (2015).
54. S. Ghatak *et al.*, NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. *Mol. Psychiatry*, (2020).
55. P. Xia, H. S. Chen, D. Zhang, S. A. Lipton, Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. *J. Neurosci.* **30**, 11246-11250 (2010).
56. G. E. Hardingham, Y. Fukunaga, H. Bading, Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat. Neurosci.* **5**, 405-414 (2002).
57. S. Okamoto *et al.*, Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. *Nat. Med.* **15**, 1407-1413 (2009).
58. A. Moldavski, J. Behr, H. Bading, C. P. Bengtson, A novel method using ambient glutamate for the electrophysiological quantification of extrasynaptic NMDA receptor function in acute brain slices. *J. Physiol.* **598**, 633-650 (2020).
59. A. Araque, R. P. Sanzgiri, V. Parpura, P. G. Haydon, Calcium elevation in astrocytes causes an NMDA receptor-dependent increase in the frequency of miniature synaptic currents in cultured hippocampal neurons. *J. Neurosci.* **18**, 6822-6829 (1998).
60. N. B. Hamilton, D. Attwell, Do astrocytes really exocytose neurotransmitters? *Nat. Rev. Neurosci.* **11**, 227-238 (2010).
61. S. A. Sloan, J. Andersen, A. M. Pasca, F. Birey, S. P. Pasca, Generation and assembly of human brain region-specific three-dimensional cultures. *Nat. Protoc.* **13**, 2062-2085 (2018).
62. S. A. Sloan *et al.*, Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. *Neuron* **95**, 779-790 e776 (2017).
63. G. Quadrato *et al.*, Cell diversity and network dynamics in photosensitive human brain organoids. *Nature* **545**, 48-53 (2017).
64. A. A. Pollen *et al.*, Establishing cerebral organoids as models of human-specific brain evolution. *Cell* **176**, 743-756 e717 (2019).
65. S. P. Kamath, A. I. Chen, Myocyte enhancer factor 2C regulates dendritic complexity and connectivity of cerebellar Purkinje cells. *Mol. Neurobiol.* **56**, 4102-4119 (2019).
66. G. E. Lyons, B. K. Micales, J. Schwarz, J. F. Martin, E. N. Olson, Expression of MEF2 genes in the mouse central nervous system suggests a role in neuronal maturation. *J. Neurosci.* **15**, 5727-5738 (1995).
67. J. A. Gorski *et al.*, Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. *J. Neurosci.* **22**, 6309-6314 (2002).
68. J. L. Rubenstein, M. M. Merzenich, Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav.* **2**, 255-267 (2003).
69. J. Mariani *et al.*, FOXG1-Dependent Dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. *Cell* **162**, 375-390 (2015).

70. V. S. Sohal, J. L. R. Rubenstein, Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. *Mol. Psychiatry* **24**, 1248-1257 (2019).
71. K. Okita *et al.*, A more efficient method to generate integration-free human iPS cells. *Nat. Methods* **8**, 409-412 (2011).
72. H. T. Liu, B. A. Tashmukhamedov, H. Inoue, Y. Okada, R. Z. Sabirov, Roles of two types of anion channels in glutamate release from mouse astrocytes under ischemic or osmotic stress. *Glia* **54**, 343-357 (2006).
73. A. Spandidos, X. Wang, H. Wang, B. Seed, PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. *Nucleic Acids Res.* **38**, D792-799 (2010).
74. S. Okamoto *et al.*, Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 3974-3979 (2002).
75. A. Dobin *et al.*, STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).
76. S. Heinz *et al.*, Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576-589 (2010).
77. A. Shcheglovitov *et al.*, SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. *Nature* **503**, 267-271 (2013).

Acknowledgments: The authors wish to thank Scott R. McKercher and other members of the Lipton laboratory for helpful discussions and insight. Fig. 2D and fig. S10 were created with BioRender.com.

Funding: This work was supported in part by NIH grants RF1 AG057409, R01 AG056259, R01 DA048882, R01 NS086890 and DP1 DA041722, California Institute for Regenerative Medicine (CIRM) award DISC2-11070 (to S.A.L.), and postdoctoral fellowship grant #11721 from Autism Speaks, Inc. (to D.T).

Author contributions:

Conceptualization: D.T, S.G., R.A., S.A.L.

Investigation: D.T, S.G, J.P. M.T, T.G., S.M.N., M.T, M.L., N.D., C.B., K.L., A.S., S.F.C.

Formal analysis: D.T., S.G., A.C., Y.C., R.K., R.A., S.A.L.

Resources: P.S., I.B., P.K.

Writing – original draft preparation: D.T, S.G., S.A.L.

Writing – review and editing: D.T, S.G., S.A.L

Supervision: N.S., M.G.R., N.N., D.H.G., R.A., S.A.L.

Funding acquisition: S.A.L.

Competing interests:

The authors declare that S.A.L. is an inventor on worldwide patents for the use of memantine and NitroSynapsin for neurodegenerative and neurodevelopmental disorders. Per Harvard University guidelines, S.A.L. participates in a royalty-sharing agreement with his former institution Boston Children's Hospital/Harvard Medical School, which licensed the drug memantine (Namenda®) to Forest Laboratories/Actavis/Allergan/AbbVie, Inc. NitroSynapsin is licensed to EuMentis Therapeutics, Inc. The other authors declare no financial conflicts of interest. All data are available in the main text or the supplementary materials

Figures and Figure Legends

Fig. 2. ChIP-seq and RNA-seq analyses show MEF2C effects on hiPSC-derived cell types. (A) Top gene ontology (GO) terms for hits found in ChIP-seq analysis of the 198 MEF2C binding targets in hNPCs. (B) List of miRNAs identified that contain binding sites for MEF2C. (C) Relative gene expression levels of miRNA identified by ChIP-seq in control hNPCs and hNPCs expressing constitutively active MEF2 containing a VP16 transactivation domain (MEF2CA). (D) Relative gene expression of miRNA in Ctrl and MHS patient hiPSC-derived cells after 2 weeks in culture. (E) β 3-tubulin (β 3-tub or TUB11) early neuronal marker expression in Ctrl1 hiPSC-derived cells expressing available miRNA inhibitors compared to non-target control inhibitor after 2 weeks in culture. (F) S100 β astrocytic marker expression in Ctrl1 cells expressing miRNA inhibitors compared with non-target control inhibitor after 2 weeks in culture. (G) Schematic diagram of miRNA effect on neurogenesis and

gliogenesis. **(H)** GO terms for differentially expressed neuronal genes by RNA-seq after 5 weeks in culture in MHS patient hiPSC-neurons vs. Ctrl. **(I)** Top differentially-expressed genes from RNA-seq showing higher expression in MHS hiPSC-neurons vs. Ctrl. **(J)** Top differentially expressed genes from RNA-seq showing lower expression in MHS hiPSC-neurons vs. Ctrl. **(K)** NRXN3 mRNA expression in all MHS patients combined vs. Ctrl. Data are mean + SEM. Sample sizes (*n*) are listed above bars from at least 3 independent experiments. **P* < 0.05, ***P* < 0.01 by ANOVA with Dunnett's post-hoc test for multiple comparisons or by two-tailed Student's *t* test for single comparisons.

Fig. 3. MHS hiPSC-derived cerebrocortical neurons show increased excitation and decreased inhibition. (A) Representative traces of glutamate- and GABA-evoked currents (each at 100 μ M). (B and C) Quantification of glutamate and GABA current density. (D) Ratio of glutamate to GABA current densities. (E) Representative patch-clamp recordings of evoked AMPAR-EPSCs at holding potential ($V_h = -70$ mV) and NMDAR-EPSCs ($V_h = +60$ mV). (F and G) Input-output curves of evoked AMPAR-EPSCs and NMDAR-EPSCs. (H and I) Quantification of peak current amplitude of evoked AMPAR-EPSCs and NMDAR-EPSCs. Data are mean $\pm$ SEM. Number of neuronal recordings (n) listed above bars from at least 4 experiments in each case. * $P < 0.05$, ** $P < 0.01$; *** $P < 0.001$, **** $P < 0.0001$ by ANOVA with Dunnett's post-hoc test for multiple comparisons (see Methods).

Fig. 4. MHS hiPSC-derived cerebrocortical neurons exhibit disrupted synaptic transmission. (A) Representative mEPSCs recorded at -70 mV in the presence of 1 μ M TTX from Ctrl1 and MHS hiPSC-neurons in culture for 5 weeks. (B and C) Cumulative probability and quantification of mean mEPSC amplitude and interevent interval (inversely related to frequency). Cumulative probability of MHS mEPSC interevent interval was significantly decreased compared to Ctrl ($P < 0.0001$ by Kolmogorov-Smirnov test). (D) Representative mIPSCs recorded at 0 mV. (E and F) Cumulative probability and quantification of mean mIPSC amplitude and interevent interval. Cumulative probability of MHS mIPSC interevent interval was significantly increased compared to Ctrl ($P < 0.0001$ by Kolmogorov-Smirnov test). (G) Representative images of β 3-tubulin, VGLUT1, VGAT, and Hoechst STOP in Ctrl1 and MHS hiPSC-neurons. Scale bar, 100 μ m. (H) Quantification of VGLUT1 in various MHS hiPSC-neurons compared to Ctrl1. (I) Quantification of VGAT in various MHS patient neurons compared to Ctrl1. (J) Quantification of the VGLUT1/VGAT ratio in various MHS patients. (K) Summary of VGLUT1/VGAT in Ctrl1 vs. MHS as a group. Data are mean + SEM. Number of neuronal recordings or imaged fields (n) listed above bars from at least 4 experiments in each case. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ by ANOVA with Dunnett's post-hoc test for multiple comparisons (see Methods).

Fig. 5. NitroSynapsin normalizes spontaneous calcium transients and neural network activity in MHS hiPSC-derived cerebrocortical neurons. (A) Spontaneous neuronal calcium transients recorded

from individual Ctrl1 and MHS hiPSC-neurons loaded with Fluo-4 AM. **(B)** Quantification of Ca^{2+} transient frequency for events with rise times <200 ms. **(C)** Representative calcium traces showing decrease in spontaneous calcium transient frequency after application of $10\ \mu\text{M}$ NitroSynapsin (NitroSyn). **(D)** Quantification of calcium transient frequency before and after application of NitroSynapsin. **(E)** Quantification of difference in normalized fluorescence ($\Delta F/F_{0\text{Drug}} - \Delta F/F_{0\text{Control}}$) as area under the curve (AUC) in response to NitroSynapsin. **(F)** Representative heat maps and raster plots of MEA recordings from Ctrl and MHS hiPSC neurons before (w/o) and after treatment with $5\ \mu\text{M}$ NitroSynapsin. Boxes outline examples of network bursts. **(G-J)** Quantification of MEA recordings by mean firing rate, electrode burst frequency (representing bursting of individual neurons), network burst frequency (representing bursting of the entire neural network), and synchronous firing. Ctrl represents pooled data for Ctrl1 and Ctrl 2. Data are mean $\pm$ SEM. Sample size listed above bars represents number of cells analyzed in 5-10 independent experiments. $*_{\#}P < 0.05$, $**_{\#}P < 0.01$, $***_{\#}P < 0.001$, $****_{\#}P < 0.0001$ by ANOVA for comparison with Ctrl value (*), or within a group (#) for without treatment (w/o) vs. NitroSynapsin treatment; for panel D, comparison was made by non-parametric Kruskal-Wallis test (see Methods).

Fig. 6. NitroSynapsin abrogates hypersynchronous burst activity in MHS cerebral organoids. (A) Representative heat maps and single traces from Ctrl1 and MHS hiPSC-derived cerebral organoids in individual MEA wells at 3-4 months of age. (B) Representative raster plots of MEA recordings in Ctrl and MHS cerebral organoids. Boxes outline examples of network bursts. (C) Representative raster plots and heat maps of MEA recordings in Ctrl and MHS cerebral organoids after treatment with NitroSynapsin (NitroSyn). (D-F) Quantification of MEA mean firing rate, network burst frequency, and synchrony index. Data are mean $\pm$ SEM. Sample size is listed above bars from 6-7 separate cerebral organoids recorded for each genotype. Ctrl includes data from Ctrl1. * $\#P < 0.05$, ** $\#P < 0.01$, *** $\#P < 0.001$, **** $\#P < 0.0001$ by ANOVA for comparison with Ctrl value (*), or within a group (#) for without treatment (w/o) vs. NitroSynapsin treatment (see Methods).

Materials and Methods

hiPSC reprogramming and maintenance

The use of human cells was approved by the institutional review boards of the Scintillon Institute and The Scripps Research Institute (TSRI; IRB-19-7428). hiPSCs were generated from patient fibroblasts, by using an integration-free reprogramming method (71), which uses three episomal vectors that collectively encode OCT3/4, SOX2, KLF4, L-MYC, LYN28, and p53-shRNA. hiPSCs were characterized for pluripotency, karyotypic integrity and generation of all three germ layers. hiPSCs were routinely cultured and maintained in our laboratory using a protocol described previously (33) with some modifications. Briefly, hiPSCs were plated on Matrigel coated plates (Corning, #354248) and cultured using mTeSR1 (STEMCELL Technologies, #05850) changed daily. The colonies were manually passaged weekly, using StemPro™ EZPassage™ Disposable Stem Cell Passaging Tool (Thermo-Fisher Scientific, #23181010).

Generation of MEF2C deletion by CRISPR/Cas9

Ctrl1 hiPSCs (Hs27, ATCC #CRL-1634; see **table S1**) were used to produce the MEF2C deletion isogenic line at the Yale Stem Cell Center, which used CRISPR/Cas9 to generate an 11bp deletion in MEF2C. Single clones were picked and further sequenced by Sanger sequencing. An isogenic line with an 11bp deletion was further characterized by whole-exome gene sequencing. No off-target effects were detected in coding regions. The isogenic line also maintained its pluripotency.

Neuronal differentiation

Differentiation of hiPSCs was performed using standard protocols for generating cerebrocortical neurons (33, 34). Briefly, feeder-free hiPSCs cultured on Matrigel were induced to differentiate by exposure for 2 week to a cocktail of small molecules: 2 μ M each of A83-01, dorsomorphin, and PNU74654 in DMEM/F12 medium supplemented with 20% Knock Out Serum Replacement (Invitrogen). Cells were then scraped manually to form floating neurospheres and maintained for 2 weeks in DMEM/F12 medium supplemented with N2 and B27 (Invitrogen) and 20 ng ml⁻¹ of basic FGF (R&D Systems). Subsequently neurospheres were seeded on polyornithine/laminin-coated dishes to form rosettes that were manually picked, expanded and frozen down as human neural progenitor cells (hNPCs). For terminal differentiation into neurons, hNPCs were plated onto polyornithine/laminin-coated glass coverslips or plates at a density of 1.5x10⁶ cells/cm² in DMEM/F12 medium supplemented with N2 and B27. For the first 2 days, 0.1 μ M of compound E (γ secretase inhibitor, CAS 209986-17-4, Calbiochem) was added. Starting on the third day, the medium was supplemented with GDNF (20 ng ml⁻¹) and BDNF (20 ng ml⁻¹).

For electrophysiological analysis and RNA-seq experiments, hNPCs were plated at a 1:1 ratio with neonatal mouse astrocytes onto polyornithine/laminin-coated glass coverslips in DMEM/F12 medium supplemented with B27, N2, GDNF (20 ng ml⁻¹), and BDNF (20 ng ml⁻¹) (Peprotech), and 0.5% FBS (Invitrogen). Prior to electrophysiology experiments, cells at week 3 of terminal differentiation were switched to BrainPhys medium (STEMCELL Technologies), and experiments were conducted after a total of 5–6 weeks of differentiation. Our protocol produced 8–15% inhibitory neurons, as monitored by immunocytochemistry with anti-GABA antibody (33).

hiPSC-derived cerebral organoid cultures

Cerebral organoids were generated as previously described (61). In brief, spheroids were generated from hiPSCs using SMAD inhibitors, dorsomorphin and SB-4321542 for 5 days. From day 6, spheroids were transferred to Neurobasal medium supplemented with EGF and FGF-2 for 19 days. From day 25, the

medium was supplemented with BDNF and NT3 until day 43, and from then on, the organoids were maintained in Neurobasal medium only. Cerebral organoids were maintained on an orbital shaker until used in experiments as described below. Histology was performed after 2 to 3 months of differentiation. At 3-4 months of age, the cerebral organoids were used for multielectrode array (MEA) analysis.

Primary astrocytes

Primary astrocytes cultures were prepared as previously described (72). Mice used for astrocyte cultures were housed and maintained in the animal facility at the Scintillon Institute or The Scripps Research Institute, and all experiments complied with protocols approved by the Institute Animal Care Committee (IACUC protocol, 17-0022-2). The brains from 1- to 2-day-old C57BL/6 mouse pups were rapidly harvested, and the meninges were removed. Brains were dissociated using mechanical means (pipettes and scissors) and enzymatic dissociation (0.25% trypsin for 30 min at 37 °C). The cell suspension was then filtered through a 70-µm cell strainer and cultured in DMEM:F12 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Two weeks after initial isolation, cells were dissociated with Accutase (STEMCELL Technologies, #07920), and the suspension was seeded onto glass coverslips coated with 20 µg/cm² poly-L-ornithine (Sigma-Aldrich, #P4638), 2 µg/cm² laminin (Trevigen, #3400-010-01), and 2 µg/cm² fibronectin (Trevigen, #3420-001-01) at a density of 25,000 cells/cm².

Immunoblots

Cells were lysed with cell lysis buffer (Cell Signaling Technologies, #9803) supplemented with protease inhibitor cocktail (Roche, #04693159001) and 10 µM SDS. Protein concentrations were determined using Pierce™ BCA Protein Assay Kit (Thermo-Fisher Scientific, #23225). Polyacrylamide gels (Novex, 8-12%) were used for protein separation prior to transfer onto nitrocellulose membrane, blockade with

blocking buffer (Li-Cor) for 1h, washing with TBST, and reaction overnight at 4 °C with mouse anti-MAP2 (1:2,000; Sigma-Aldrich, #M4403, RRID:AB_477193) and then mouse anti-GAPDH (1:10,000; Sigma-Aldrich, #CB1001 EMD MILLIPORE, RRID:AB_2107426). Membranes were then reacted with goat anti-mouse infrared (IR) dye-conjugated secondary antibody (Li-Cor antibody, #926-32210, RRID AB_621842) for 1 h at room temperature (RT). The membrane was scanned using an Odyssey® scanner, quantified using Fiji software, and analyzed with Prism 7.04 software (GraphPad).

Transfection with miRNA inhibitor

Ctrl1 hNPCs were transfected with miRNA inhibitors using HiPerFect Transfection reagent (Qiagen, #301705) according to the manufacturer's instructions. The following inhibitors were used (purchased from Qiagen): hsa-miR-663b miRCURY LNA miRNA Inhibitor (YI04100013); hsa-miR-4273 miRCURY LNA miRNA Inhibitor (YI04105965); negative control A miRCURY LNA miRNA Inhibitor Control (YI00199006). After 48 h, the medium was replaced with fresh medium, and cells were maintained for an additional 2 weeks before being fixed and stained.

Quantitative (q)RT-PCR

For total RNA, RNA was extracted using a Quick-RNA™ MiniPrep kit (Zymo Research, #R1055), and each sample was reverse transcribed using a QuantiTect Reverse transcription kit (Qiagen, #205313). qRT-PCR reactions were performed with LightCycler 480 SYBR Green I MasterMix (Roche) in a LightCycler480II instrument (Roche). The primer sequence was designed using Primer Bank (73). NRXN3: F- AGTGGTGGGCTTATCCTCTAC; R- CCCTGTTCTATGTGAAGCTGGA. S100β: F- TGGCCCTCATCGACGTTTTC; R- ATGTTC AAAGAACTCGTGGCA. The following primers were purchased from Qiagen: SOX2, NANOG, Lin28, β3-tubulin. Data were normalized to 18s rRNA expression, and analyzed with Prism 7.04 software (GraphPad).

miRNA was extracted using a mirVana™ miRNA Isolation Kit (Thermo Fisher, #AM1560), and each sample was reverse transcribed using miScript II RT Kit (Qiagen, #218161). qRT-PCR reactions were performed with miScript SYBR Green PCR Kit (Qiagen, #218075) in a LightCycler480II instrument (Roche). The following primers were purchased from Qiagen: miR-663b (MS00037884), miR-663 (MS00037247), miR-4273 (MS00021280). Data were normalized to RNU6-2 expression, and analyzed with Prism 7.04 software (GraphPad).

Histological imaging and immunocytochemistry

For 2D cultures, hiPSC colonies, hNPCs, or neurons at 2 time-points of differentiation (1 and 3 months) were fixed with 4% PFA for 15 min and washed 3 times with PBS. Phase-contrast images of 2-month-old 3D organoids were acquired on an EVOS cell imaging system (Thermo-Fisher Scientific) for size measurements. Two to three-month-old cerebral organoids were fixed in 4% PFA at 4 °C overnight followed by serial incubation in 15% and 30% sucrose in PBS overnight. Fixed organoids were embedded in tissue freezing medium (TFM, General Data, Cincinnati, OH), and were flash frozen with isopentane and liquid nitrogen. Frozen organoids were sectioned in a cryostat using optimal cutting temperature (OCT) compound and then sectioned at 15-μm thickness. Cells or sections were blocked with 3% BSA and 0.3% Triton X-100 in PBS for 30 min. For synaptic staining, cultures were blocked with 3% BSA and 0.1% Saponin (wt/vol) in PBS. Cells/sections were incubated with primary antibody in blocking solution overnight at 4 °C and then washed with PBS. The appropriate Alexa Fluor (488, 555, 647) conjugated secondary antibodies were used at 1:1,000, plus Hoechst 33342, Trihydrochloride, Trihydrate dye (1:1,000, Thermo-Fisher Scientific, #H3570) to visualize nuclei for 1 h at RT.

Primary antibodies and dilutions were as follows: Rabbit anti-NANOG (1:500, Cell signaling technologies, #4903s, RRID:AB_10559205); mouse anti-TRA1-60 (1:500, Cell Signaling Technologies, #4746s, RRID:AB_2119059); rabbit anti-SOX2 (1:500, Cell Signaling Technologies, #3579s,

RRID:AB_2195767); mouse anti-Nestin (1:250, Abcam, #ab22035, RRID:AB_446723); mouse anti-S100 β (1:1,000, Abcam, #ab11178, RRID:AB_297817); rabbit anti-GFAP (1:500, Agilent, #Z0334, RRID:AB_10013382); mouse anti-MAP2 (1:500, Sigma-Aldrich, #M4403, RRID:AB_477193); chicken anti- β 3-tubulin (1:500, Abcam, #ab41489, RRID:AB_727049); guinea pig anti-VGLUT1 (1:250, Synaptic Systems, #135304, RRID:AB_887878); mouse anti-VGAT (1:250, Synaptic Systems, #131011, RRID:AB_887872); rabbit anti-synapsin I (1:500, Millipore, AB1543p, RRID:AB_90757); mouse anti-PSD95 (1:500, Invitrogen, MA1-045, RRID:AB_325399); rat anti-CTIP2 (1:150; Abcam, #ab18465, RRID:AB_2064130); rabbit anti-TBR2 (1:300; Abcam, #ab23345, RRID:AB_778267); rabbit anti-TBR1 (1:250, Abcam, #ab31940, RRID:AB_2200219). Coverslips were mounted on slides with fluorescent mounting medium (DAKO) and visualized with a Zeiss Axiovert (100M) epifluorescence microscope or ImageXpress automated high-content confocal microscopy (Molecular Devices). For synaptic staining of PSD95 and synapsin I, punctae were visualized using a Nikon A1 confocal microscope. Imaging conditions were identical for each set of stains (e.g. exposure time and laser power). Quantification of GFAP, MAP2, nestin, TBR2, TBR1, CTIP2, synapsin I, and PSD-95 were performed with Fiji software. The number of synapses was calculated as co-localized punctae of synapsin I/PSD-95 staining per neurite length identified with β 3-tubulin. Quantification of S100 β , β 3-tubulin, VGLUT1, and VGAT were performed using MetaXpress (Molecular Devices). Quantification of immunostained cells was performed in a masked fashion, normalized to cell number (by Hoechst staining for cell nuclei), and compared with the same masking/thresholding settings.

Luciferase gene reporter assays

Luciferase reporter assay was performed as previously described with some modifications (39). Briefly, hNPCs were transfected with MEF2 luciferase reporter (74) along with *Renilla* luciferase control vector using a Human Stem Cell Nucleofector Kit according to the manufacturer's instructions (Lonza, VPH-5012). Cells were plated in a 96-well plate and terminally differentiated into neurons. Cells were

harvested at various time points of differentiation over a period of 11 days and then analyzed using a Dual-Glo luciferase assay kit (Promega) following the manufacturer's instructions. Firefly luciferase activity was normalized to *Renilla* luciferase activity.

RNA-seq data acquisition, mapping, and analysis

After 5 weeks in culture, hiPSC-derived neurons grown on mouse neonatal astrocytes were processed for analysis. The following patient samples were used for the RNA sequencing: control samples Ctrl1, Ctrl2, and Ctrl4, and patient mutations MHS-P1, MHS-P2, MHS-P3, and MHS-P4 (see **table S1**). RNA was extracted using a Quick-RNA™ MiniPrep kit (Zymo Research, #R1055). RNA was quality checked before sequencing by RNA screenTape (Agilent tape station) and nanodrop. All RNA samples had an RNA integrity number (RIN) >9. RNA libraries were prepared via Ribo depletion. Sequencing was performed on the Illumina HiSeq2500 platform in a 1x75 bp single end (SR) configuration in high output mode (V4 chemistry) with 40 million reads per sample. Reads were aligned to the latest human hg38 reference genome using the STAR spliced read aligner (75). No read trimming or filtering was done with this data set because the quality distribution and variance appeared normal. Total counts of read-fragments aligned to known gene regions within the human hg38 refSeq reference annotation were used as the basis for quantification of gene expression. Fragment counts were derived using HTS-seq program using hg38 Ensembl transcripts as model. Various QC analyses were conducted to assess the quality of the data and to identify potential outliers. Differentially expressed genes (DEGs) were identified using three bioconductor packages, EdgeR, Limma+Voom and Limma, which were then considered and ranked based on adjusted *P*-values (FDR) of ≤ 0.1 . Gene set enrichment analysis (GSEA) was performed using the top DEGs (determined by EdgeR). DEGs were selected based on several false discovery rate (FDR) Benjamini-Hochberg adjusted *P*-values and simple *P*-values. A total of 1029 genes were used for the

enrichment analysis. Of the neuronal-relevant GO terms, the most differentially expressed genes were further analyzed by qPCR to validate the results.

ChIP-seq and qRT-PCR

ChIP assays were performed using the *ChIP-IT Express Kit* (Active Motif) according to the manufacturer's instructions. **Briefly**, $\sim 2 \times 10^7$ hNPCs were used per ChIP experiment. The hNPCs were first dissociated with Accutase and crosslinked with 1% paraformaldehyde, and then the nuclei were sonicated 10 times for 20 s at maximum settings using a Misonix Sonicator (Misonix, Farmingdale, NY). Sheared chromatin was immunoprecipitated with 4 μ g MEF2 antibody (#sc-313, Santa Cruz Biotechnology, RRID:AB_631920) or control IgG (Active Motif) antibody. At this stage of development, hNPCs express primarily the MEF2C isoform of the MEF2 transcription factor family. ChIP DNA samples were subjected to qPCR assay. We determined the enrichment of specific DNA sequences after ChIP using an EXPRESS SYBR® GreenERT™ detection kit (Invitrogen) on a Mx3000P real time PCR system (Stratagene). Levels of enrichment after ChIP were calculated using the comparative cycle threshold method (Invitrogen) after normalizing with IgG control, as we have previously described (35, 36). ChIP DNA samples were also subjected to preparation for ChIP-Seq Library according to Illumina's Chip-Seq Sample prep kit. ChIP-seq samples were sequenced with an Illumina Genome Analyzer II system (San Diego, CA) according to the manufacturer's instructions and aligned to the University of California, Santa Cruz (UCSC) *Homo sapiens* reference genome (hg18) using Bowtie. The aligned reads were processed with HOMER v2.6 software and visualized on the UCSC genome browser (76). Peaks were predicted and annotated with HOMER v2.6 software (**table S3**).

Electrophysiology and pharmacology experiments

Whole-cell recordings were performed with patch electrodes of 3 to 5 M Ω resistance. To analyze voltage-gated currents, pipettes were filled with an internal solution composed of (in mM): K-gluconate, 120; KCl, 5; MgCl₂, 2; HEPES, 10; EGTA, 10; Mg-ATP, 4; pH 7.4 and mOsm 290. The external solution was composed of Ca²⁺ and Mg²⁺-free Hank's Balanced Salt Solution (HBSS; GIBCO) to which were added: CaCl₂, 2 mM; HEPES, 10 mM; and glycine, 20 mM. Recordings were performed using a Multiclamp 700B amplifier (Molecular Devices) at a data sampling frequency of 2 kHz with an analog-to-digital convertor, Digidata 1440A (Molecular Devices). Voltage-clamp and current-clamp protocols were applied using Clampex v10.6 (Molecular Devices). Preliminary analysis and offline filtering at 500 Hz were achieved using Clampfit v10.6 (Molecular Devices).

Agonist-induced currents (glutamate- and GABA-evoked) were recorded at a holding potential of -70 mV in the nominal absence of extracellular Mg²⁺ and in the presence of 20 μ M glycine (Sigma) and tetrodotoxin (TTX, 1 μ M, Hello Bio). Agonist was applied via a rapid gravity-flow, local superfusion system. The internal solution for these recordings was (in mM): CsCl, 135; MgCl₂, 2; HEPES, 10; EGTA, 1; Mg-ATP, 4; pH 7.4 and mOsm 290.

Evoked postsynaptic currents were induced by brief (1 ms) unipolar current pulses (0.1–0.9 mA) from an external stimulator (A365, WPI) using a stimulating electrode (CBAEC75, FHC) positioned at a distance of 100–150 μ m from the cell soma (77).

Spontaneous postsynaptic currents (sPSCs) were recorded at a holding potential of -70 mV and 0 mV in gap-free mode as described in previously (33). The internal solution contained (in mM): K-gluconate, 120; KCl, 5; MgCl₂, 2; HEPES, 10; EGTA, 10; Mg-ATP, 4; pH 7.4 and mOsm 290. Miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) were recorded at -70 mV and 0 mV, respectively, at 21 °C after equilibrium in TTX (1 μ M) for at least 20 min. The internal solution used for recording mEPSCs and mIPSCs was comprised of (in mM): Cs-gluconate 130; CsCl 5; MgCl₂, 2; HEPES, 10; EGTA, 1; Mg-ATP, 4; pH 7.4 and mOsm 290. Mini Analysis

software (Synapstosoft, Fort Lee, NJ) was used to calculate the frequency and amplitude of spontaneous synaptic events.

Extrasynaptic currents were pharmacologically isolated and measured by whole-cell patch clamp recordings of hiPSC-derived cerebrocortical neurons based on previously published protocols (56, 58). Briefly, continuous recordings of individual neurons were performed in gap free mode at -70 mV in control conditions, followed by application of bicuculline (50 μ M, a GABA_A receptor antagonist, Tocris) for 1 min to inhibit inhibitory synaptic inputs and activate synaptic glutamate receptors. Subsequently, the synaptic NMDARs thus activated were blocked by application of the open-channel irreversible antagonist MK-801 (10 μ M, Tocris) in the continued presence of bicuculline for 5 min, followed by a 30 min wash with external solution. The residual current recorded after the wash was analyzed as extrasynaptic current. Thereafter, memantine or NitroSynapsin was applied to the neuron to study its effect on this current since these drugs have been shown to predominantly inhibit eNMDARs (32, 53, 55).

Calcium imaging

For monitoring the relative change in intracellular Ca²⁺ concentration vs. time, Fluo-4 (Fluo 4 AM/Fluo 4 direct, Life Technologies) was used according to the manufacturer's instructions and a previously published protocol (54). To monitor Fluo-4 fluorescence changes, randomly selected fields of comparable cell density were excited at 480 nm with an exposure time of 30 ms, imaged using a 40X oil objective at 33 frames per second, and analyzed with MetaMorph software (Molecular Devices). Changes in intracellular Ca²⁺ from baseline (F_0) to peak fluorescence (ΔF) were expressed as fractional changes above baseline ($\Delta F/F_0$). Events with $\Delta F/F$ rise times of <200 ms were considered neuronal transients. Neurons were distinguished from astrocytes morphologically, as verified with cell-type specific antibody staining in previously published experiments (33). Calcium imaging movies using Fluo-4 were prepared at 500 frames per second using ImageJ (NIH).

eNMDAR-mediated Ca^{2+} changes were isolated using the previously published protocol with bicuculline and MK-801 delineated above (56). After washing out the MK-801 for 30 min, subsequent changes in intracellular Ca^{2+} levels represented eNMDAR activity, which could be blocked by NitroSynapsin (32, 53).

Multielectrode array (MEA) recording

MEA recordings were obtained as previously described (52). Cells were plated on CytoView 12-well plates (Axion Biosystems) coated with 0.1% polyethyleneimine (PEI) and 10 $\mu\text{g}/\text{ml}$ laminin. Based upon pilot experiments performed to determine when neuronal properties developed, we recorded from 2D cultures 5–6 weeks after neuronal differentiation from hNPCs, and from cerebral organoids at 3–4 months of development. Recordings were performed on a Maestro MEA (Axion Biosystems) using the “neural broadband analog mode” setting with a sampling frequency of 12.5 kHz in control conditions and after NitroSynapsin treatment at 37 °C and analyzed with Axion Biosystems Maestro Axis Software (version 2.4.2). For calculating firing frequency, an electrode displaying >5 spikes per min was considered active. A network burst was defined as a minimum of 25 electrodes displaying >10 spikes per electrode at <100 ms inter-spike interval. Network burst frequency was calculated as total number of network bursts recorded per second during the analysis window expressed in Hz. Synchronous firing was determined by analyzing a 20 ms synchrony window, which is the time window around zero used for computing the area under the cross-correlation curve. Analysis of well-wide, pooled interelectrode cross-correlation gives the synchrony index, defined as a unitless measure of synchrony between 0 and 1 such that values closer to 1 indicate higher synchrony.

Data analysis and statistics

For each experiment, we used at least 3 independent sets of cultures from separate differentiations or 3 independent groups of cerebral organoids from separate differentiations. Sample size was determined from prior power analyses based on prior data obtained in our laboratory. All data were acquired by an investigator blinded to the sample groups. No data was excluded from analysis. Data are presented as mean $\pm$ SEM. Statistical analyses were performed using GraphPad Prism software. Statistical significance was determined by a two-tailed unpaired Student's *t* test for single comparisons, by ANOVA followed by a post hoc Dunnett's test for multiple comparisons, or by a Sidak's test corrected for multiple comparisons between selected pairs. For non-parametric data such as percentage change in calcium event frequency, we used a Kruskal-Wallis test followed by a post hoc Dunn's test for multiple comparisons. For analysis of cumulative distributions, we used the Kolmogorov-Smirnov test performed with Mini Analysis software (Synapstosoft, Fort Lee, NJ). Data with *P* values < 0.05 were considered to be statistically significant. In general, the variance was similar between groups being compared. No samples or data were excluded from the analysis.

Supplementary Figures

Fig. S1. Generation of hiPSCs from patient fibroblasts. (A) Immunocytochemistry showing expression of pluripotency markers SOX2, Nanog and Tra1-60 in all hiPSC lines. Scale bar, 100 μm. (B) qPCR analysis of pluripotency markers SOX2, Nanog and Lin28 for several clones generated for each MHS patient hiPSC vs. Ctrl fibroblasts. Data are mean + SEM. Sample size listed above bars (number of replicates).

Fig. S2. MHS patient hNPC characterization. (A) Immunocytochemistry of SOX2 and Nestin markers in Ctrl and MHS patient hiPSC-derived hNPCs. Scale bars, 100 μ m. (B) Immunocytochemistry of S100 β and Hoechst in neurons differentiated from Ctrl and MHS hiPSCs after 1 month. Scale bars, 50 μ m. (C) Quantification of S100 β expression. (D) Immunocytochemistry of MAP2 in Ctrl1 and MHS-P3 patient hiPSC-derived neurons at 3 months. Scale bars, 100 μ m. (E) Quantification of MAP2 expression in 3-month-old neurons from Ctrl and MHS. Data are mean + SEM. Sample size listed above bars (number of replicates in 3 independent experiments). * $P < 0.05$, *** $P < 0.001$ by Student's t test.

Fig. S4. Both Ctrl and MHS hiPSC-derived cerebrocortical neurons fire action potentials (APs) in current clamp, and manifest sodium and potassium currents under voltage-clamp. (A) Patch-clamp recording of evoked APs in hiPSC-derived neurons from a holding potential (V_h) of -60 mV in current-clamp mode. Current-injection protocol used to evoke APs illustrated below traces. **(B)** Representative sodium and potassium currents in voltage-clamp mode elicited by voltage steps from V_h = -60 mV after a prepulse to -90 mV for 300 ms. Voltage protocol illustrated below traces.

Fig. S5. MHS hiPSC-derived cerebrocortical neurons exhibit increased excitatory synaptic activity and decreased inhibitory synaptic activity. (A) Representative spontaneous (s)EPSCs recorded at -70 mV from Ctrl and MHS hiPSC-neurons in culture for 5 weeks. (B and C) Quantification of sEPSC mean amplitude and frequency. (D) Representative sIPSCs recorded at 0 mV from Ctrl and MHS hiPSC-neurons in culture for 5 weeks. (E and F) Quantification of sIPSC mean amplitude and frequency. Data are mean $\pm$ SEM. Sample size (n) listed above bars from 3-5 experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ by ANOVA with Dunnett's post hoc test for multiple comparisons.

Fig. S6. MHS hiPSC-derived cerebrocortical neurons exhibit fewer synapses. (A) Representative images of β 3-tubulin, PSD-95, synapsin I, and merged image for Ctrl and MHS patients. Scale bar, 10 μ m. (B) Quantification of number of synapses (coincident synapsin I/PSD-95 punctae staining) per neurite length for Ctrl and MHS patients. Data are mean + SEM. Number of imaged fields (*n*) listed above bars from 3 separate experiments. * $P < 0.05$, **** $P < 0.0001$ by ANOVA with Dunnett's post hoc test for multiple comparisons.

Fig. S7. NitroSynapsin inhibits aberrant basal eNMDAR-responses in MHS hiPSC-derived cerebrocortical neurons. (A). Mean $\pm$ SEM envelope of calcium responses and their inhibition by NitroSynapsin (NitroSyn) monitored with Fluo-4 in Ctrl and MHS neurons after pharmacological isolation of eNMDARs. The protocol for isolating eNMDAR responses consisted of activation and subsequent blockade of synaptic NMDAR-mediated currents by bicuculline (BIC) and MK-801, respectively. Blue-dotted line added to show Ca^{2+} response before and after NitroSynapsin. (B) Quantification of basal eNMDAR-mediated Ca^{2+} responses and effect of NitroSynapsin. Responses before treatment (bright bars with positive values, signifying the amplitude of eNMDAR-mediated response) and after treatment (NitroSynapsin; pale bars with negative values, representing inhibition of the eNMDAR-mediated response). (C) Mean $\pm$ SEM envelope of calcium traces from Ctrl and MHS hiPSC-neurons after pharmacological isolation of eNMDAR-mediated responses in the presence of TTX. (D) Mean $\pm$ SEM envelope of calcium traces showing inhibition with APV in Ctrl and MHS neurons after pharmacological isolation of eNMDAR-mediated responses. (E) Patch-clamp recordings from Ctrl and MHS hiPSC-neurons demonstrating pharmacological isolation of eNMDAR-mediated current and its inhibition by NitroSynapsin. Sample size listed in each panel. $^{*}\#P < 0.05$, $^{***},####P < 0.0001$ by ANOVA with post hoc Dunnett's test for comparison with Ctrl (*) or with post hoc Sidak's test between w/o and NitroSynapsin (#) for each genotype.

Fig. S8. MHS hiPSC-derived cerebrocortical organoids generate fewer neurons. (A) Representative phase-contrast images of 2-month-old Ctrl and MHS organoids. Scale bar, 2 mm. (B) Quantification of the organoid diameter. (C) Representative images of β 3-tubulin, S100 β , and Hoechst for Ctrl and MHS hiPSC-neurons. *Left panel*: Low power images of whole organoids. *Right panel*: Higher power images of individual fluorescence channels. Scale bar, 100 μ m. (D) Quantification of β 3-tubulin fluorescence intensity for each MHS line normalized to Hoechst and relative to Ctrl. (E) β 3-tubulin mRNA expression by qRT-PCR for grouped MHS hiPSC-neurons vs. Ctrl. (F) Quantification of S100 β fluorescence

intensity for each MHS line normalized to Hoechst and relative to Ctrl. **(G)** S100 β mRNA expression by qRT-PCR in Ctrl vs. MHS as a group. **(H)** Representative images of GFAP, β 3-tubulin, and Hoechst for Ctrl and MHS cerebral organoids. Scale bar, 50 μ m. **(I)** Quantification of GFAP fluorescence intensity for MHS cerebral organoids normalized to Hoechst and relative to Ctrl. **(J)** Quantification of GFAP fluorescence intensity in Ctrl vs. MHS cerebral organoids as a group. **(K)** GFAP mRNA expression by qRT-PCR in Ctrl vs. MHS organoids as a group. Data are mean + SEM. Number of imaged fields (*n*) from 3 separate cerebral organoids (C and E) or number of organoids analyzed by qRT-PCR (C, E and F) are listed above bars. **P* < 0.05; ***P* < 0.01; ****P* < 0.001 by ANOVA with Dunnett's post hoc test for multiple comparisons or by unpaired Student's *t* test for single comparisons.

Fig. S9. MHS hiPSC-derived cerebrocortical organoids display disrupted layering. (A)

Representative images from left to right of Nestin, TBR2, CTIP2, TBR1, and Hoechst for Ctrl and MHS patients. Scale bar, 50 μ m. **(B)** Quantification of Nestin fluorescence intensity for each MHS line relative to Ctrl. Fluorescence was normalized to Hoechst (labeling DNA in nucleus) to correct for cell number.

(C) TBR2 fluorescence intensity for each MHS line normalized to Hoechst and relative to Ctrl. **(D)**

CTIP2 fluorescence intensity for each MHS line normalized to Hoechst and relative to Ctrl. **(E)** TBR1

fluorescence intensity for each MHS line normalized to Hoechst and relative to Ctrl. Data are mean $\pm$ SEM. Sample size is 3-4 sections from 3 separate cerebral organoids for each genotype. * $P < 0.05$; **** $P < 0.0001$ by ANOVA with Dunnett's post hoc test.

Fig. S10. Aberrant gliogenesis and excitation in MEF2C autism patient hiPSC-neurons. Schematic diagram showing that MHS hiPSCs generate more astrocytes and fewer cerebrocortical neurons. Compared to control (Ctrl), the MHS neuronal population consists of fewer inhibitory neurons and excitatory neurons, but with more VGLUT1 vesicles, resulting in increased presynaptic glutamate release,

increased postsynaptic intracellular Ca^{2+} levels, and hence increased excitability. The novel eNMDAR antagonist NitroSynapsin ameliorates this hyperactivity.

ID	Genotype	Age	Sex	Notable symptoms	hiPSC generated	Reference
Ctrl1	WT	neonatal	M	Isogenic control for MHS-P2	Skin biopsy	22
Ctrl2	WT	18 y	M			23
Ctrl3	WT	8 y	F		Coriell	
Ctrl4	WT	1 y	M		Skin biopsy	
MHS-P1	A106C (S36R)	3 y	M	Averabal	Skin biopsy	
MHS-P2	Exon 1 del	neonatal	M	Isogenic to Ctrl1 by CRISPR/Cas9		
MHS-P3	Exon 1 del	6 y	M	Averbal, seizures	Skin biopsy	16
MHS-P4	C52T (Q18X)	4 y	F	Averbal, seizures	Skin biopsy	

Table S1. Details of patients contributing fibroblasts for hiPSC generation.

Intrinsic properties	Ctrl1 (70)	Ctrl2 (25)	MHS-P1 (64)	MHS-P2 (40)	MHS-P3 (55)	MHS-P4 (60)
Cell Capacitance (pF)	18.1±0.8	20.9±1.3	15.8±0.9	18.2±0.9	21.5±1.2	16.5±1.1
Sodium current density (pA/pF)	70.0±6.2	59.4±10.2	65.0±8.5	85.6±10.8	79.6±7.7	64.1±4.0
Potassium current density (pA/pF)	96.0±6.7	100.5±7.4	120.1±13.5	113.2±20.4	93.9±9.0	117.2±10.0
Resting Membrane Potential (mV)	-30.5±1.1	-30.1±1.7	-28.4±1.3	-31.6±1.3	-32.9±1.6	-29.1±1.0
Action Potential (AP) height (mV)	91.9±2.4	87.2±2.6	89.7±2.4	97.6±2.0	96.3±1.8	91.5±1.9
AP half-width (ms)	8.5±0.5	9.4±0.8	8.6±0.6	7.3±0.6	7.0±0.5	7.5±0.4
AP threshold (mV)	-28.4±0.5	-29.9±1.0	-27.9±0.6	-27.1±0.8	-28.9±0.8	-26.8±0.6

Table S2. Electrophysiological properties of Ctrl and MHS hiPSC-derived cerebrocortical neurons.

Table S3. ChIP-seq targets of transcription factor MEF2 (see separate excel file).

Movie S1. Ctrl hiPSC-derived cerebrocortical neuron and astrocyte cultures. Fluo-4 measurement of intracellular Ca^{2+} showing low basal endogenous signaling activity.

Movie S2. MHS hiPSC-derived cerebrocortical neuron and astrocyte cultures. Fluo-4 measurement of intracellular Ca^{2+} showing high synchronous burst-like basal endogenous signaling activity.

Movie S3. Effect of NitroSynapsin on MHS hiPSC-derived cerebrocortical neuron and astrocyte cultures. Fluo-4 measurement of intracellular Ca^{2+} showing increased excitability, which was normalized after application of 10 μM NitroSynapsin.